Xanomeline
in COBENFY
Pronunciation: zan-OE-me-leen
“The gnome line”
Light blue → cholinergic / muscarinic
Hypersalivation if not paired with trospium
Urinary urgency/frequency if not combined with trospium
What it isM1 and M4 muscarinic agonist, given with trospium; schizophrenia.
Why this oneThe first antipsychotic in decades that does not block D2, so there is no extrapyramidal or prolactin effect.
What limits itPeripheral cholinergic effects — nausea, vomiting, sweating — are why trospium is co-formulated.
FDA-approved for
- schizophrenia (with trospium) (2024)
NO BOXED WARNINGS
Principal riskPeripheral cholinergic effects — nausea, vomiting, sweating — which is exactly why trospium is c
Classes and tags
Clinical profile
Defining liabilityPeripheral cholinergic adverse effects and syncope
Open Xanomeline in the interactive console ↗
Memory aids: interaction avatars
Open Xanomeline in the interactive console ↗
Self-check
- Which muscarinic receptors does xanomeline activate?
M1 and M4. - Why is trospium co-formulated with xanomeline?
To counter peripheral cholinergic effects.